Equillium Announces Abstract Accepted for Presentation at ACR Convergence 2022
September 15 2022 - 8:00AM
Business Wire
Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology
company focused on developing novel therapeutics to treat severe
autoimmune and inflammatory disorders with high unmet medical need,
today announced that an abstract was accepted for presentation at
ACR Convergence, the annual meeting of the American College of
Rheumatology. The meeting, the world’s premier virtual rheumatology
experience, will take place online November 10 – 14, 2022 at the
Pennsylvania Convention Center in Philadelphia, Pennsylvania.
Title: Urine ALCAM is a Strong Predictor of Lupus
Nephritis First Author: Dalena Chu, Associate Scientist,
Equillium, Inc. Session Title: SLE – Diagnosis,
Manifestations, and Outcomes Poster II: Manifestations Session
Type: Virtual Poster Date and Time: 1:00 pm – 3:00 pm
ET, Sunday, November 13, 2022 Abstract Number: 1478
The abstract highlights that levels of urinary soluble ALCAM
(sALCAM) is a potential biomarker of disease severity in lupus
nephritis that could be indicative of a patient’s response to
treatment. Analyses are in progress to evaluate sALCAM in
combination with other measures of disease severity to predict
longer term disease outcomes.
About Systemic Lupus Erythematosus (SLE) / Lupus Nephritis
(LN)
Systemic lupus erythematosus is an autoimmune disease in which
the immune system attacks its own tissues, causing widespread
inflammation and tissue damage in the affected organs. It can
affect the joints, skin, brain, lungs, kidneys, and blood vessels.
Lupus nephritis is a serious complication of SLE, occurring in
approximately 30% – 60% of individuals with SLE. In LN, the body’s
own immune system attacks the kidneys, causing inflammation and
significantly reducing kidney function over time.
About Itolizumab
Itolizumab is a clinical-stage, first-in-class anti-CD6
monoclonal antibody that selectively targets the CD6-ALCAM pathway.
This pathway plays a central role in modulating the activity and
trafficking of T cells that drive a number of immuno-inflammatory
diseases. Equillium acquired rights to itolizumab through an
exclusive partnership with Biocon Limited.
About Equillium
Equillium is a clinical-stage biotechnology company leveraging a
deep understanding of immunobiology to develop novel therapeutics
to treat severe autoimmune and inflammatory disorders with high
unmet medical need. The company’s pipeline consists of the
following novel immunomodulatory assets targeting
immuno-inflammatory pathways. Itolizumab, a first-in-class
monoclonal antibody that targets the CD6-ALCAM signaling pathway
which plays a central role in the modulation of effector T cells,
is currently in a Phase 3 study for patients with acute
graft-versus-host disease (aGVHD) and is in a Phase 1b study for
patients with lupus/lupus nephritis. EQ101, a first-in-class
tri-specific cytokine inhibitor that selectively targets IL-2,
IL-9, and IL-15, is Phase 2 ready and expected to begin enrolling
patients in an alopecia areata study in the second half of 2022.
EQ102, a bi-specific cytokine inhibitor that selectively targets
IL-15 and IL-21, is ready for clinical development and expected to
begin enrolling patients in a Phase 1 study anticipated to include
normal healthy volunteers and celiac disease patients, in the
second half of 2022.
For more information, visit www.equilliumbio.com.
Forward Looking Statements
Statements contained in this press release regarding matters
that are not historical facts are "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act
of 1995. Forward-looking statements may be identified by the use of
words such as "anticipate", "believe", “could”, “continue”,
"expect", "estimate", “may”, "plan", "outlook", “future” and
"project" and other similar expressions that predict or indicate
future events or trends or that are not statements of historical
matters. Because such statements are subject to risks and
uncertainties, many of which are outside of the Company’s control,
actual results may differ materially from those expressed or
implied by such forward-looking statements. Such statements
include, but are not limited to statements regarding the potential
benefit sALCAM as a potential biomarker and indicator of a
patient’s potential responsiveness to treatment; the potential
benefit of treating patients with aGVHD or lupus/lupus nephritis
with itolizumab, Equillium’s plans and expected timing for
developing itolizumab including the expected timing of initiating,
completing and announcing further results from the EQUALISE study,
Equillium’s plans and expected timing for developing EQ101 and
EQ102 including the expected timing of initiating, completing and
announcing further results from Phase 2 and Phase 1 studies,
respectively, the potential for any of Equillium’s ongoing or
planned clinical studies to show safety or efficacy, and
Equillium’s plans and expected timing for developing its product
candidates and potential benefits of its product candidates. Risks
that contribute to the uncertain nature of the forward-looking
statements include: uncertainties related to the abilities of the
leadership team to perform as expected; Equillium’s ability to
execute its plans and strategies; risks related to performing
clinical studies; the risk that interim results of a clinical study
do not necessarily predict final results and that one or more of
the clinical outcomes may materially change as patient enrollment
continues, following more comprehensive reviews of the data, and as
more patient data become available; potential delays in the
commencement, enrollment and completion of clinical studies and the
reporting of data therefrom; the risk that studies will not be
completed as planned; Equillium’s plans and product development,
including the initiation and completion of clinical studies and the
reporting of data therefrom; whether the results from clinical
studies will validate and support the safety and efficacy of
Equillium’s product candidates; changes in the competitive
landscape; uncertainties related to Equillium’s capital
requirements; having to use cash in ways or on timing other than
expected and the impact of market volatility on cash reserves; and
economic, business, competitive, and/or regulatory factors
affecting the businesses of Equillium and Metacrine generally.
These and other risks and uncertainties are described more fully
under the caption "Risk Factors" and “Management’s Discussion and
Analysis of financial Condition and Results of Operations” sections
of their respective Annual Report on Form 10-K and Quarterly
Reports on Form 10-Q, their Current Reports on Form 8-K and other
and SEC filings and reports, which may be accessed for free by
visiting EDGAR on the SEC web site at http://www.sec.gov and on
Equillium’s and Metacrine’s respective website under the heading
“Investors.” Investors should take such risks into account and
should not rely on forward-looking statements when making
investment decisions. All forward-looking statements contained in
this press release speak only as of the date on which they were
made. Equillium and Metacrine undertake no obligation to update
such statements to reflect events that occur or circumstances that
exist after the date on which they were made.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220915005475/en/
Investor Contact Michael Moore Vice President, Investor
Relations & Corporate Communications 619-302-4431
ir@equilliumbio.com
Equillium (NASDAQ:EQ)
Historical Stock Chart
From Mar 2024 to Apr 2024
Equillium (NASDAQ:EQ)
Historical Stock Chart
From Apr 2023 to Apr 2024